ZYME

Zymeworks Inc. Common Stock

ZYME, USA

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies that enable the selective modulation of recruited cytotoxic immune cells for various therapeutic applications; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidate consists of zanidatamab, a novel bispecific antibody that targets human epidermal growth factor receptor 2 HER2 that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. In addition, the company develops a pipeline of preclinical product candidates. It has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

https://www.zymeworks.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ZYME
stock
ZYME

Norges Bank Buys New Shares in Zymeworks Inc. $ZYME MarketBeat

Read more →
ZYME
stock
ZYME

Zymeworks to Engage in Key Investor Conferences MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$34.5

Analyst Picks

Strong Buy

7

Buy

1

Hold

2

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

6.03

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-6.12 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-4.93 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-115.24 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.24

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 101.20% of the total shares of Zymeworks Inc. Common Stock

1.

EcoR1 Capital, LLC

(30.3298%)

since

2025/06/30

2.

Rubric Capital Management LP

(6.2197%)

since

2025/06/30

3.

Bvf Inc

(5.6895%)

since

2025/06/30

4.

Morgan Stanley - Brokerage Accounts

(5.5161%)

since

2025/06/30

5.

Redmile Group, LLC

(5.4804%)

since

2025/06/30

6.

BlackRock Inc

(5.0099%)

since

2025/06/30

7.

Vanguard Group Inc

(3.2543%)

since

2025/06/30

8.

UBS Asset Mgmt Americas Inc

(3.2475%)

since

2025/06/30

9.

BNP Paribas Investment Partners SA

(2.6931%)

since

2025/06/30

10.

HBM Healthcare Investments AG Ord

(2.6362%)

since

2025/06/30

11.

Vanguard Total Stock Mkt Idx Inv

(2.4364%)

since

2025/07/31

12.

Blackstone Inc

(2.1876%)

since

2025/06/30

13.

Deutsche Bank AG

(2.0397%)

since

2025/06/30

14.

Prosight Management, LP

(1.7296%)

since

2025/06/30

15.

Perceptive Advisors LLC

(1.6839%)

since

2025/06/30

16.

iShares Russell 2000 ETF

(1.6074%)

since

2025/08/31

17.

Dimensional Fund Advisors, Inc.

(1.5745%)

since

2025/06/30

18.

Vestal Point Capital LP

(1.5184%)

since

2025/06/30

19.

Nextech Invest, Ltd.

(1.4708%)

since

2025/06/30

20.

TANG CAPITAL MANAGEMENT LLC

(1.4524%)

since

2025/06/30

21.

BNP Paribas US Small Cap ClassicC

(1.4374%)

since

2025/07/31

22.

State Street Corp

(1.4372%)

since

2025/06/30

23.

UBS Lux Dgtl Hlth Eq Fd seeding P acc

(1.1153%)

since

2025/07/31

24.

BNP Paribas Health Cr Innovtr Cl Cap

(1.0506%)

since

2025/07/31

25.

Xtrackers S&P 500 Swap ETF 1C

(1.0225%)

since

2025/07/31

26.

Geode Capital Management, LLC

(0.9314%)

since

2025/06/30

27.

Nuveen, LLC

(0.8647%)

since

2025/06/30

28.

Xtrackers S&P 500 2xLev Dly Swap ETF 1C

(0.8347%)

since

2025/07/31

29.

Fidelity Small Cap Index

(0.6491%)

since

2025/06/30

30.

Nuveen Quant Small Cap Equity R6

(0.6231%)

since

2025/07/31

31.

iShares Russell 2000 Growth ETF

(0.5745%)

since

2025/08/31

32.

iShares Biotechnology ETF

(0.5353%)

since

2025/08/31

33.

Jupiter Merian Glb Eq AbsRet I USD Acc

(0.4449%)

since

2025/06/30

34.

DFA US Small Cap I

(0.3322%)

since

2025/07/31

35.

Vanguard Russell 2000 ETF

(0.3085%)

since

2025/07/31

36.

Schroder Global Healthcare A Acc

(0.2913%)

since

2025/07/31

37.

Dimensional US Small Cap ETF

(0.2517%)

since

2025/08/29

38.

Invesco MSCI World ETF

(0.2447%)

since

2025/07/31

39.

State St Russell Sm Cap® Indx SL Cl I

(0.2436%)

since

2025/08/31

40.

Federated Hermes MDT SCC Institutional

(0.227%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.26

EPS Estimate

-0.3164

EPS Difference

0.0564

Surprise Percent

17.8255%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Fair Value(3.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.